Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for lung cancer patients: experimental drug shrinks tumors after other treatments fail

NCT ID NCT01802632

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called AZD9291 in 603 people with advanced non-small cell lung cancer whose tumors had started growing again after previous targeted therapy. The main goals were to find the safest and most effective dose, measure how the drug moves through the body, and see if it could shrink tumors. The results helped decide the best dose for future studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED (INOPERABLE) NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED (INOPERABLE) NON SMALL CELL LUNG CANCER ADVANCED NON SMALL CELL LUNG CANCER

Contacts and locations

Locations

  • Research Site

    Aurora, Colorado, 80045, United States

  • Research Site

    Atlanta, Georgia, 30322, United States

  • Research Site

    Boston, Massachusetts, 02114, United States

  • Research Site

    Boston, Massachusetts, 02215, United States

  • Research Site

    Charlotte, North Carolina, 28204, United States

  • Research Site

    Nashville, Tennessee, 37232, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    Heidelberg, 3084, Australia

  • Research Site

    Kogarah, 2217, Australia

  • Research Site

    Nedlands, 6009, Australia

  • Research Site

    Pierre-Bénite, 69310, France

  • Research Site

    Saint-Herblain, 44805, France

  • Research Site

    Villejuif, 94800, France

  • Research Site

    Cologne, 50924, Germany

  • Research Site

    Essen, 45122, Germany

  • Research Site

    Würzburg, 97080, Germany

  • Research Site

    Genova, 16100, Italy

  • Research Site

    Orbassano, 10043, Italy

  • Research Site

    Roma, 00144, Italy

  • Research Site

    Chiba, 260-8717, Japan

  • Research Site

    Fukuoka, 811-1395, Japan

  • Research Site

    Fukuoka, 812-8582, Japan

  • Research Site

    Habikino-shi, 583-8588, Japan

  • Research Site

    Hirakata-shi, 573-1191, Japan

  • Research Site

    Hiroshima, 730-8518, Japan

  • Research Site

    Kanazawa, 920-8641, Japan

  • Research Site

    Kashiwa, 227-8577, Japan

  • Research Site

    Kobe, 650-0047, Japan

  • Research Site

    Matsuyama, 790-0007, Japan

  • Research Site

    Okayama, 700-8558, Japan

  • Research Site

    Shinjuku-ku, 160-0023, Japan

  • Research Site

    Sunto-gun, 411-8777, Japan

  • Research Site

    Takatsuki-shi, 569-8686, Japan

  • Research Site

    Yokohama, 221-0855, Japan

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Seoul, 6351, South Korea

  • Research Site

    Madrid, 08035, Spain

  • Research Site

    Madrid, 28041, Spain

  • Research Site

    Seville, 41013, Spain

  • Research Site

    Tainan, 704, Taiwan

  • Research Site

    Taipei, 10002, Taiwan

  • Research Site

    Manchester, M20 4BX, United Kingdom

  • Research Site

    Newcastle upon Tyne, NE7 7DN, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.